Agenus Will Present Cancer Research in Phoenix
The company will share clinical and translational data at the upcoming SITC 2026 Annual Meeting in November.
Updated on Oct. 2, 2026 in Cancer
Agenus will present two research posters at the SITC 2026 Annual Meeting in Phoenix, Arizona, on November 7, 2026. The presentations will share new insights from ongoing clinical trials involving botensilimab and balstilimab.
Why it matters
The upcoming presentations offer a look at the long-term survival outcomes for patients with metastatic colorectal cancer treated with experimental immunotherapy combinations. This research provides critical visibility into the efficacy of these novel treatment protocols.
Clinical trials for these immunotherapies include 1,300 patients who received botensilimab and/or balstilimab, while 900 of those participants were evaluated with balstilimab alone.
The players
Agenus
Founded in 1994, this biotechnology company focuses on the development of immunotherapies for cancer patients.
Anthony El-Khoueiry
He is a medical expert slated to present clinical trial data at the November conference.
Shanmugarajan Krishnan
He is a researcher scheduled to present translational findings regarding immunotherapy combinations.
The details
Anthony El-Khoueiry will present clinical data regarding long-term survivors of metastatic colorectal cancer, while Shanmugarajan Krishnan will present translational research on a combination involving agenT-797. Both sessions are scheduled to take place within the Exhibition Halls of the North Building.
Timeline
Agenus was founded in 1994.
The SITC 2026 Annual Meeting will take place from November 4-8, 2026.
Research posters will be presented on November 7, 2026.
The Big Picture
The upcoming presentations follow the established pattern of sharing immunotherapy developments at the SITC 2026 Annual Meeting.
The findings presented at the meeting could eventually influence future treatment options for patients with metastatic colorectal cancer. Patients should consult their oncologists to understand how these evolving immunotherapy protocols may impact their personal care plans.
The takeaway
These presentations reflect the ongoing evolution of immunotherapy combinations designed to improve survival in complex cancer cases. Residents and patients should monitor updates from the conference for potential shifts in the standard of care.
Further reading
For more on advancements in oncology, visit the Cancer section.
